This supports the hypothesis that the AVWS was directly linked to the activity of the CD20-positive lymphoma cells, rather than to the circulating M-protein produced by CD20-negative plasma cells - a notion reinforced by rituximab’s known limited efficacy in plasma cell-driven disorders [5]. The gene discussed is MYOM2; the disease is lymphoma.